Acumen Pharmaceuticals, Inc.
ABOS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | -0.01 | 0.03 | -0.03 |
| FCF Yield | -29.44% | -45.32% | -51.37% | -26.37% |
| EV / EBITDA | -3.45 | -1.59 | -2.36 | -2.70 |
| Quality | ||||
| ROIC | -21.38% | -28.37% | -16.39% | -18.72% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.15 | 0.78 | 1.18 | 0.73 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 4.25% | 6.90% | -25.67% | -10.65% |
| Safety | ||||
| Net Debt / EBITDA | 0.63 | 0.17 | 0.04 | 0.16 |
| Interest Coverage | -24.82 | -39.91 | -29.69 | -38.18 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.28 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -11,227.50 |